Nicotine Citron Sans Sucre, Édulcorée Au Xylitol, À L'acésulfame Potassique, Au Sucralose Et Au Malt (Nicotine Resinate)

Nicotine Resinate, the active ingredient in Nicotine Citron Sans Sucre, Édulcorée Au Xylitol, À L'acésulfame Potassique, Au Sucralose Et Au Malt, is a nicotine replacement therapy presented as an oromucosal formulation for oral mucosal use. It is intended to aid adults who are trying to quit smoking by reducing nicotine withdrawal symptoms and cravings.

GNH USA supplies Nicotine Citron Sans Sucre, Édulcorée Au Xylitol, À L'acésulfame Potassique, Au Sucralose Et Au Malt as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nicotine Resinate is employed in nicotine replacement therapy to support smoking cessation.

- Smoking cessation: helps reduce withdrawal symptoms and cravings associated with quitting tobacco. - Tobacco dependence: provides controlled low‑dose nicotine to facilitate transition away from cigarettes. - Relapse prevention: supports maintenance of abstinence after initial quitting by stabilizing nicotine levels.

Nicotine Resinate may be associated with several adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Mouth irritation: mild soreness or tingling in the oral cavity. - Nausea: transient feeling of queasiness after use. - Headache: mild to moderate head discomfort. - Dizziness: brief light‑headed sensation. - Hiccups: occasional involuntary diaphragm spasms. - Altered taste: temporary metallic or bitter taste.

Serious or Rare Side Effects: - Allergic reaction: rash, itching, or angioedema requiring medical attention. - Throat swelling: may cause difficulty breathing or swallowing. - Severe hypotension: sudden drop in blood pressure. - Cardiac arrhythmia: irregular heart rhythm in susceptible individuals. - Seizures: rare neurologic event requiring emergency care.

When using Nicotine Resinate, certain precautions should be observed to ensure safe and effective therapy.

- Assess nicotine dependence: evaluate the patient’s smoking history and level of dependence before initiating therapy. - Cardiovascular risk: avoid use in patients with recent myocardial infarction or unstable angina, as nicotine can increase heart rate and blood pressure. - Blood pressure monitoring: observe for transient elevations in hypertensive individuals. - Concurrent nicotine products: do not combine with other nicotine replacement products to prevent excess nicotine exposure. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Nicotine Resinate can interact with other medicines, altering its effects or increasing the risk of adverse events.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may potentiate nicotine’s sympathomimetic effects. - CYP2A6 inhibitors (e.g., methoxsalen): can raise nicotine plasma concentrations. - Insulin: nicotine may affect glucose metabolism, requiring dose adjustment.

Moderate Interactions (Monitor Closely): - Beta‑blockers: nicotine may diminish their antihypertensive efficacy. - Selective serotonin reuptake inhibitors (SSRIs): may increase the likelihood of nausea and dizziness.